This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
by Ekta Bagri
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
BMYNegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
by Ahan Chakraborty
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
by Ekta Bagri
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
by Ekta Bagri
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
NVSNegative Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
by Zacks Equity Research
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
VRTXNegative Net Change BEAMNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
CRMDNegative Net Change ZYMENegative Net Change IMVTNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
NBIXNegative Net Change CRMDNegative Net Change XENENegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
by Zacks Equity Research
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
BIIBNegative Net Change BAYRYNegative Net Change CRMDNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
by Ahan Chakraborty
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Ekta Bagri
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
GILDNegative Net Change INONegative Net Change DERMNegative Net Change ZVRANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
by Zacks Equity Research
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
CRMDNegative Net Change IOVANegative Net Change GMABNegative Net Change IMCRNegative Net Change
biotechs cell-therapy medical
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
by Zacks Equity Research
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
REGNNegative Net Change CRMDNegative Net Change NTLANo Net Change IMCRNegative Net Change
biotechnology biotechs earnings gene-therapy medical pharmaceuticals
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
by Zacks Equity Research
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
AZNNegative Net Change RHHBYNegative Net Change JNJNegative Net Change AMGNNegative Net Change
biotechs
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
by Zacks Equity Research
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
PBYINegative Net Change CRMDNegative Net Change EXASNegative Net Change IMCRNegative Net Change
biotechs earnings
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
by Sundeep Ganoria
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
CRBPNo Net Change CGCNegative Net Change TLRYPositive Net Change HRMYNegative Net Change GTBIFNegative Net Change
biotechs marijuana medical pot-stocks
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
by Zacks Equity Research
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
GSKNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
CRMDNegative Net Change EXASNegative Net Change MIRMNegative Net Change IMCRNegative Net Change
biotechs earnings
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
by Zacks Equity Research
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
SNYNegative Net Change NVAXNegative Net Change CRMDNegative Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
CPRXNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
CRMDNegative Net Change ACADNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
by Zacks Equity Research
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
RHHBYNegative Net Change SRPTNegative Net Change ARWRNo Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
by Zacks Equity Research
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
CRMDNegative Net Change ADMANo Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
NVOPositive Net Change LLYNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
RHHBYNegative Net Change JNJNegative Net Change HALONegative Net Change IMCRNegative Net Change
biotechs earnings
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
by Zacks Equity Research
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
BEAMNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechs earnings